MJA
MJA

"I want the one for older women" — extending the human papillomavirus vaccine population base

Jeffrey H J Tan and Michael A Quinn
Med J Aust 2008; 189 (9): . || doi: 10.5694/j.1326-5377.2008.tb02158.x
Published online: 3 November 2008

To the Editor: Wain’s criticism of the Australian Therapeutic Goods Administration (TGA) approval of the bivalent vaccine, Cervarix (GlaxoSmithKline), suggesting it did not adhere to World Health Organization guidelines,1 should not detract from the potential benefits of human papillomavirus (HPV) vaccination in women over 26 years of age.

Online responses are no longer available. Please refer to our instructions for authors page for more information.